Wegovy and Breastfeeding: Why It Is Not Recommended

The biggest misconception: 'It probably passes out of the body quickly, so it should be fine'

A widely held assumption is that because Wegovy is injected weekly and the body processes it gradually, any trace in breast milk would be negligible. That reasoning is understandable, but it is not what the evidence supports, and regulators do not accept it as a basis for use during breastfeeding.

Semaglutide is a large-molecule GLP-1 receptor agonist with a half-life of roughly one week, meaning it remains active in the body for an extended period after each dose. Studies in rats found semaglutide present in milk, and while animal data cannot be directly translated to humans, the finding is sufficient for the MHRA and Novo Nordisk to advise that breastfeeding should not continue during treatment. The NHS semaglutide medicines page reflects this guidance.

The absence of robust human data is, itself, the problem. Clinical trials of Wegovy excluded breastfeeding women, so there is no dataset showing how much semaglutide transfers into human milk or whether a nursing infant would be affected. Until that evidence exists, the precautionary position stands. Telling a patient it is probably fine based on a pharmacokinetic hunch is not something any responsible prescriber would do, and it is not something our clinical team at nume would do either.

What 'not recommended while breastfeeding on Wegovy' actually means in practice

Guidance distinguishing what is contraindicated from what is not recommended matters here. Wegovy falls into the latter category: the prescribing information advises against use, rather than issuing an absolute prohibition backed by documented harm. In practice, this distinction rarely changes the outcome, no responsible UK prescriber will initiate or continue Wegovy in someone who is actively breastfeeding.

If you became pregnant while already on Wegovy and continued into the postnatal period, or if you started treatment without disclosing that you were breastfeeding, stop and speak to your GP or the prescribing service that supplied your treatment. Our contact team can help you reach a prescriber if you are a nume patient in that situation.

After stopping Wegovy, there is no universally agreed washout period published in the UK SmPC for a return to breastfeeding. Given the one-week half-life, meaningful clearance takes several weeks. Your own prescriber or GP should give you a specific timeframe based on how long you were on treatment and the dose you reached. More detail on this question is on a dedicated page.

Weight management while breastfeeding: what the evidence does support

The period after birth is one where many people reasonably want to think about their weight, and it is worth being direct: breastfeeding itself supports a modest calorie deficit naturally, and the NHS guidance on healthy weight covers safe approaches to managing weight postnatally without medicine.

Orlistat is also not recommended while breastfeeding. That leaves lifestyle approaches as the primary evidence-based route during this period. A GP, dietitian or health visitor can help you build a plan. These conversations are worth having rather than waiting until you have finished breastfeeding and then trying to compress treatment into a shorter window.

When breastfeeding does end and you want to explore whether Wegovy or another licensed weight-loss injection is suitable, a full clinical assessment will consider your BMI, health history and any weight-related conditions. The NHS England guidance on weight management injections sets out the clinical criteria. Our free consultation is the starting point if you want to explore private treatment at that stage, a GPhC-registered prescriber reads your answers the same day. If approved, the treatment arrives via DPD the next working day in plain, unbranded packaging, tracked to your door.

The situation for people who were on Wegovy and became pregnant

This is a separate but related question our prescribers hear regularly. Wegovy is not recommended in pregnancy either, the same absence of safety data applies, and animal studies have shown embryo-foetal harm at high doses. If you discover you are pregnant while on treatment, stop immediately and contact your GP. The Wegovy and pregnancy page covers this in full, including what to do about ongoing monitoring and how to tell your midwifery team.

For those planning a pregnancy in the future: MHRA guidance advises using effective contraception while on semaglutide and for a period after stopping before trying to conceive. Patients in Wegovy Liverpool clinics and elsewhere are given this same timeframe by their prescriber. The breastfeeding and semaglutide page covers the mechanism question in more depth if you want to understand why the guidance is framed the way it is, and if you have questions about everyday habits during treatment, such as drinking coffee on Wegovy, that page also addresses common lifestyle queries.